SDCBP2 and neoplasm: Through bioinformatics analysis and in vitro experiments, we demonstrated that SDCBP2, as a potential therapeutic target, is an independent prognostic biomarker for LUAD, and inhibiting its expression may suppress tumor progression by affecting the cell cycle, apoptosis and ferroptosis.